CANC
Oncology ETF

Invest in Oncology Innovation and the Fight Against Cancer.

LEARN MORE

Share Price:

$36.56

February 09, 2026

Factsheet

How to Invest

Why Invest in CANC?

Breakthrough Innovation

Oncology continues to witness breakthrough medical innovation, powering new treatments and saving more lives.

Impact & Scale

Cancer remains the second deadliest killer in the world today, forecast to affect one in two people in their lifetime.

Source: National Cancer Institute.

Investment Expertise

CANC is managed by a veteran investor with over 20-year investment track record covering these companies.

Fund Overview

Fund Details

As of February 09, 2026

Ticker

CANC

CUSIP

87975E701

Fund Inception Date

08/14/23

Net Expense Ratio*

0.75%

Gross Expense Ratio

0.99%

AuM ($)

$151,055,522

# of Holdings

Shares Outstanding

4,140,000

Portfolio Manager

David K. Song, MD, PhD, CFA

Primary Exchange

Nasdaq

*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027

Fund Summary

The Tema Oncology ETF (CANC) seeks to invest in companies that potentially stand to benefit from further advances in oncology related biotechnology and healthcare.

CANC Overview

Summary Prospectus

Introducing CANC

Portfolio Breakdown

Top 10 holdings

As of February 09, 2026

Company

% of Nav

REVOLUTION MEDICINES INC

6.16%

BRIDGEBIO PHARMA INC

4.82%

NOVARTIS AG

4.73%

ELI LILLY & CO

4.44%

ASTRAZENECA PLC

4.34%

BRISTOL-MYERS SQUIBB CO

4.25%

ROCHE HOLDING AG

4.02%

MERCK & CO INC

3.77%

GENMAB A/S

3.39%

COGENT BIOSCIENCES INC

3.32%

Download Holdings

Country Breakdown

United States

73.50%

Switzerland

10.77%

United Kingdom

4.95%

Denmark

3.39%

Others

7.39%

Industry Breakdown

Health Care

99.10%

Cash & Cash Equivalents

0.87%

Performance
Distributions
Premium / Discount

Prices & Performance

As of

Jan 31, 2026

CANC

3 months

1 Year

3 Years

5 Years

Since inception

NAV

15.54% 21.13%

39.35% 42.78%

16.85% 16.09%

Market Price

15.50% 21.04%

39.27% 42.92%

17.03% 16.23%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.

The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

Dec 14, 2023

Dec 13, 2023

Dec 15, 2023

$0.149112

$0.134232

Dec 11, 2024

$0.72827034

$0.49959034

Dec 10, 2025

Dec 11, 2025

$0.01959053

0.2 0.31 0.3 0.28 0.06 0.26 0.15 0.14 0.2 0.2 0.23 -0.04 0.33 0.11 0.49 0.31 0.34 0.16 0.3 0.16

Premium/Discount

Сhart Table

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

2023/Q3

2023/Q4

2024/Q1

2024/Q2

2024/Q3

2024/Q4

2025/Q1

2025/Q2

2025/Q3

2025/Q4

CANC NAV / Market Price

NAV$36.49

NAV change (1D)$0.02

Median Bid/Ask Spread (30 Day)0.36%

Market Price$36.56

Market Price Change (1D)($0.02)

Premium/Discount0.2%

As of: February 09, 2026

February-26 January-26 December-25 November-25 October-25 September-25 August-25 July-25 June-25 May-25 April-25 March-25 February-25

How does the Tema CANC ETF fit in a portfolio?

Investment Style Box

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM

CANC ETF

Equity core

Where could a position be funded from?

Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
Provides a balanced exposure across key oncology areas and company risk profiles.
Could replace a satellite or a growth-oriented position.

How to Invest

*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.

Related Research & Insights

Stay informed with our latest research, insights, and market analysis to make better investment decisions.

White Paper: Healthcare’s Next Cycle is Taking Shape

An in-depth perspective on the recovery and future growth of the healthcare sector, driven by innovation and AI, as outlined in Dr David Song's latest whitepaper.

Read the Full Article

Why Healthcare is Going Back on Offense in 2026

Discover why healthcare is poised for growth in 2026, driven by policy clarity, AI advancements, and strategic M&A initiatives in pharma, biotech, and medtech.

Read the Full Article

2025 Healthcare Recovery & 2026 Green Shoots

Healthcare sector rebounded in 2025, leading to a promising 2026 with significant growth potential and innovation in the biotech industry.

Read the Full Article

Risk Information

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com.
Read the prospectus carefully before investing.

Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Oncology Companies Risk: Oncology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable.

The stock prices of oncology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.

Investing in Foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Because the Fund evaluates ESG factors to assess and exclude certain investments for non-financial reasons, the Fund may forego some market opportunities available to funds that do not use these ESG factors.

Tema ETFs LLC serves as the investment adviser to Tema Oncology ETF (the “Fund”), and NEOS Investments, LLC serves as a sub-adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema ETFs LLC nor NEOS Investments, LLC. Check the background of Foreside on FINRA’s BrokerCheck.

Get in Touch

CANC Oncology ETF

$36.56

Why Invest in CANC?

Breakthrough Innovation

Impact & Scale

Investment Expertise

Fund Overview

Fund Details

As of February 09, 2026

Fund Summary

Introducing CANC

Portfolio Breakdown

Top 10 holdings

As of February 09, 2026

Country Breakdown

United States

Switzerland

United Kingdom

Denmark

Others

Industry Breakdown

Health Care

Cash & Cash Equivalents

Prices & Performance

CANC

3 months

1 Year

3 Years

5 Years

Since inception

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

Premium/Discount

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

CANC NAV / Market Price

How does the Tema CANC ETF fit in a portfolio?

Investment Style Box

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

Where could a position be funded from?

Fund Documents

How to Invest

Related Research & Insights

White Paper: Healthcare’s Next Cycle is Taking Shape

Why Healthcare is Going Back on Offense in 2026

2025 Healthcare Recovery & 2026 Green Shoots

Subscribe for Updates

Explore our ETFs

HRTS

TOLL

RSHO

VOLT

DSPY

Risk Information

CANC
Oncology ETF